A newly introduced House Bill, H.R. 1427, the "Promoting Innovation and Access to Life-Saving Medicine Act," would amend the Public Health Services Act to provide a framework for the Food and Drug Administration (FDA) to approve and license generic versions of biologic medicines. The bill would allow the FDA broad discretion to approve bio-generics, including determining what clinical and safety studies would be necessary for their approval. H.R. 1427 would also give makers of original biologic medicines a five-year market exclusivity period, the same as is currently given for traditional chemical medicines. Similar House bills have been introduced and defeated in recent years, and H.R. 1427 has already elicited strong responses from industry and other groups, both in support of and against the bill.